En vivo
RecursionA Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions - Yahoo Finance10x Genomics Blog10x, Curio Settle Genomics Patent Suit Before Trial - Law36010x Genomics Blog10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative - simplywall.stRecursionRecursion Milestones Link AI Discovery To Clinical And Valuation Upside - Yahoo FinanceWuXi BiologicsWuXi Biologics Chengdu Milestone Raises Questions On Capacity Use And Returns - simplywall.st10x Genomics NewsWhy 10x Genomics (TXG) Stock Is Down Today - StockStoryIntuitive SurgicalBetter Than Intuitive Surgical? 1 Under-the-Radar Healthcare Stock to Buy and Hold Forever - The Globe and Mail10x Genomics BlogWhy 10x Genomics (TXG) stock is down today - MSNEdwards LifesciencesEdwards Lifesciences Stock (US28176E1082): Analyst Upgrade and Price Target Revision - AD HOC NEWSFierceBiotechTrump plans to fire FDA chief Marty Makary: report10x Genomics BlogHarvard, 10x Patent Suit Targets Newer Cell-Mapping Platform - Bloomberg Law News
Este artículo no está disponible en el archivo.